Browse

Valneva’s Shigella vaccine has been shown to reduce cases of intestinal infection, hitting the key endpoint of a phase 2 trial.

Argenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.

Novartis disclosed that nine individuals with spinal muscular atrophy who received its gene therapy Zolgensma later developed tumors. Two of the cases showed evidence that the adeno-associated vir…